'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells

Current Opinion in Immunology

Volumn 23, Issue 1, 2011, Pages 131-137

  Unger, Wendy W J ^a   Van Kooyk, Yvette ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C TYPE LECTIN RECEPTOR; CD14 ANTIGEN; CD209 ANTIGEN; DEC 205 ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LECTIN RECEPTOR; LYMPHOCYTE ANTIGEN; PROTEIN ANTIGEN DEC 205 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; T LYMPHOCYTE RECEPTOR; T6 ANTIGEN; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INNATE IMMUNITY; LANGERHANS CELL; LYMPHOCYTE SUBPOPULATION; LYMPHOID ORGAN; NONHUMAN; REVIEW;

ANIMALS; ANTIGENS; CARBOHYDRATES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; LECTINS, C-TYPE; VACCINES;

EID: 79951683467     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.11.011     Document Type: Review

References (49)

1. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
2. Gringhuis S.I., den Dunnen J., Litjens M., van der Vlist M., Geijtenbeek T.B.H. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009, 10:1081-1088.
3. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii Si, Soares H., Brimnes M.K., Moltedo B., Moran T.M., Steinman R.M. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
4. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
5. Garcia-Vallejo J.J., Van Kooyk Y. Endogenous ligands for C-type lectin receptors: the true regulators of immune homeostasis. Immunol Rev 2009, 230:22-37.
6. Cummings R.D., McEver R.P. Essentials of Glycobiology 2009, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. edn 2. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart, M.E. Etzler (Eds.).
7. Geijtenbeek T.B., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009, 9:465-479.
8. van Vliet S.J., Garcia-Vallejo J.J., van Kooyk Y. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol Cell Biol 2008, 86:580-587.
9. Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008, 8:935-947.
10. Santegoets S.J.A.M., Gibbs S., Kroeze K., van de Ven R., Scheper R.J., Borrebaeck C.A., de Gruijl T.D., Lindstedt M. Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions. J Leukoc Biol 2008, 84:143-151.
11. van der Aar A.M.G., Sylva-Steenland R.M.R., Bos J.D., Kapsenberg M.L., de Jong E.C., Teunissen M.B.M. Cutting edge: loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 2007, 178:1986-1990.
12. Klechevsky E., Liu M., Morita R., Banchereau R., Thompson-Snipes L., Palucka A.K., Ueno H., Banchereau J. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum Immunol 2009, 70:281-288.
13. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., Briere F., Chaussabel D., Zurawski G., Palucka A.K., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29:497-510.
14. Stoitzner P., Green L.K., Jung J.Y., Price K.M., Tripp C.H., Malissen B., Kissenpfennig A., Hermans I.F., Ronchese F. Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 2008, 180:1991-1998.
15. Klechevsky E., Flamar A.L., Cao Y., Blanck J.P., Liu M., O'Bar A., Gouna-Deciat O., Klucar P., Thompson-Snipes L., Zurawski S., et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, 116:1685-1697.
16. Schmitt N., Morita R., Bourdery L., Bentebibel S.E., Zurawski S.M., Banchereau J., Ueno H. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 2009, 31:158-169.
17. Sparber F., Tripp C.H., Hermann M., Romani N., Stoitzner P. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiol 2009, 215:770-779.
18. Angel C.E., Lala A., Chen C.J., Edgar S.G., Ostrovsky L.L., Dunbar P.R. CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. Int Immunol 2007, 19:1271-1279.
19. Segura E., Kapp E., Gupta N., Wong J., Lim J., Ji H., Heath W.R., Simpson R., Villadangos J.A. Differential expression of pathogen-recognition molecules between dendritic cell subsets revealed by plasma membrane proteomic analysis. Mol Immunol 2010, 47:1765-1773.
20. Shortman K., Heath W.R. The CD8+ dendritic cell subset. Immunol Rev 2010, 234:18-31.
21. Poulin L.F., Salio M., Griessinger E., Njos-Afonso F., Craciun L., Chen J.L., Keller A.M., Joffre O., Zelenay S., Nye E., et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8+ dendritic cells. J Exp Med 2010, 207:1261-1271.
22. Bachem A., Guttler S., Hartung E., Ebstein F., Schaefer M., Tannert A., Salama A., Movassaghi K., Opitz C., Mages H.W., et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010, 207:1273-1281.
23. Crozat K., Guiton R., Contreras V., Feuillet V., Dutertre C.A., Ventre E., Vu Manh T.P., Baranek T., Storset A.K., Marvel J., et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8+ dendritic cells. J Exp Med 2010, 207:1283-1292.
24. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., Chen C.J., Dunbar P.R., Wadley R.B., Jeet V., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010, 207:1247-1260.
25. Romani N., Thurnher M., Idoyaga J., Steinman R.M., Flacher V. Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 2010, 88:424-430.
26. Nchinda G., Kuroiwa J., Oks M., Trumpfheller C., Park C.G., Huang Y., Hannaman D., Schlesinger S.J., Mizenina O., Nussenzweig M.C., et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008, 118:1427-1436.
27. Bozzacco L., Trumpfheller C., Siegal F.P., Mehandru S., Markowitz M., Carrington M., Nussenzweig M.C., Piperno A.G., Steinman R.M. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A 2007, 104:1289-1294.
28. Gurer C., Strowig T., Brilot F., Pack M., Trumpfheller C., Arrey F., Park C.G., Steinman R.M., Munz C. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008, 112:1231-1239.
29. Birkholz K., Schwenkert M., Kellner C., Gross S., Fey G., Schuler-Thurner B., Schuler G., Schaft N., Dorrie J. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 2010, 116(3):2277-2285.
30. Kamphorst A.O., Guermonprez P., Dudziak D., Nussenzweig M.C. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol 2010, 185(6):3426-3435.
31. Tacken P.J., Joosten B., Reddy A., Wu D., Eek A., Laverman P., Kretz-Rommel A., Adema G.J., Torensma R., Figdor C.G. No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation. J Immunol 2008, 180:7687-7696.
32. He L.Z., Crocker A., Lee J., Mendoza-Ramirez J., Wang X.T., Vitale L.A., O'Neill T., Petromilli C., Zhang H.F., Lopez J., et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 2007, 178:6259-6267.
33. Ramakrishna V., Treml J.F., Vitale L., Connolly J.E., O'Neill T., Smith P.A., Jones C.L., He L.Z., Goldstein J., Wallace P.K., et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004, 172:2845-2852.
34. Sancho D., Mourúo-Sí D., Joffre O.P., Schulz O., Rogers N.C., Pennington D.J., Carlyle J.R., Reis e Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008, 118:2098-2110.
35. Caminschi I., Proietto A.I., Ahmet F., Kitsoulis S., Shin Teh J., Lo J.C.Y., Rizzitelli A., Wu L., Vremec D., van Dommelen S.L.H., et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008, 112:3264-3273.
36. Singh S.K., Stephani J., Schaefer M., Kalay H., Garcia-Vallejo J.J., den Haan J., Saeland E., Sparwasser T., van Kooyk Y. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol Immunol 2009, 47:164-174.
37. Singh S.K., Streng-Ouwehand I., Litjens M., Kalay H., Saeland E., Van Kooyk Y. Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses. Int J Cancer 2010, [epub available].
38. De Koker S., De Geest B., Singh S., De Rycke R., Naessens T., Van Kooyk Y., Demeester J., De Smedt S., Grooten J. Polyelectrolyte microcapsules as antigen delivery vehicles to dendritic cells: uptake, processing, and cross-presentation of encapsulated antigens. Angew Chem Intl Ed 2009, 48:8485-8489.
39. Espuelas S., Thumann C., Heurtault Bü, Schuber F., Frisch Bt. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug Chem 2008, 19:2385-2393.
40. Cruz L.J., Tacken P.J., Fokkink R., Joosten B., Stuart M.C., Albericio F., Torensma R., Figdor C.G. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010, 144:118-126.
41. Idoyaga J., Cheong C., Suda K., Suda N., Kim J.Y., Lee H., Park C.G., Steinman R.M. Cutting edge: Langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol 2008, 180:3647-3650.
42. Flacher V., Tripp C.H., Stoitzner P., Haid B., Ebner S., Del Frari B., Koch F., Park C.G., Steinman R.M., Idoyaga J., Romani N. Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol 2009, 130:755-762.
43. Mukhopadhaya A., Hanafusa T., Jarchum I., Chen Y.G., Iwai Y., Serreze D.V., Steinman R.M., Tarbell K.V., DiLorenzo T.P. Selective delivery of β-cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A 2008, 105:6374-6379.
44. Yamazaki S., Dudziak D., Heidkamp G.F., Fiorese C., Bonito A.J., Inaba K., Nussenzweig M.C., Steinman R.M. CD8+CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol 2008, 181:6923-6933.
45. Kel J., de Geus E.D., van Stipdonk M.J., Drijfhout J.W., Koning F., Nagelkerken L. Immunization with mannosylated peptide induces poor T cell effector functions despite enhanced antigen presentation. Int Immunol 2008, 20:117-127.
46. Sugimura T., Ito Y., Tananari Y., Ozaki Y., Maeno Y., Yamaoka T., Kudo Y. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008, 26:2700-2705.
47. Kunzi V., Klap J.M., Seiberling M.K., Herzog C., Hartmann K., Kursteiner O., Kompier R., Grimaldi R., Goudsmit J. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009, 27:3561-3567.
48. Berinstein N.L. Enhancing cancer vaccines with immunomodulators. Vaccine 2007, 25:B72-B88.
49. Dougan M., Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.